Enflonsia (clesrovimab) and Beyfortus (nirsevimab) are FDA approved and American Academy of Pediatrics (AAP) recommended injections that help prevent serious lung disease caused by Respiratory Syncytial Virus (RSV).

These monoclonal antibody shots are available for all infants younger than 8 months of age during RSV season (typically October 1 through March 31). Beyfortus (nirsevimab) is also available for some children 8 months to 19 months of age who are at increased risk for severe RSV disease (preterm infants with chronic lung disease, children with severe immunocompromise, children with severe cystic fibrosis, American Indian and Alaska Native children) and who are entering their second RSV season. 

Infants under 8 months of age whose mothers received the RSV vaccine (Abrysvo) during the 32nd-36th weeks of pregnancy should be protected for the season and will not need to get the RSV immunization themselves (as long as the vaccine was given 2 weeks before delivery).

The latest data on these RSV antibody products show that there is an 80-90% decrease in RSV hospitalizations for healthy, full term infants who received either of these immunizations.

If you would like your child to get this recommended immunization this fall, please contact your insurance company to ensure coverage, then call our office at 434-975-7777 to schedule an appointment.